跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
OXLUMO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
OXLUMO
Authorized
STANDARD
OXLUMO
Alnylam Netherlands BV
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4990579d003c7935
Company
Alnylam Netherlands BV
Type
Standard
Approval Details
Approval Id
4990579d003c7935
Drug Approval Canada Name
OXLUMO
Product Name
OXLUMO
Status
Marketed
Status Date
2022-05-05
Original Market Date
2022-05-05
Din
02525755
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription
Ahfs
92:92.00
Atc Original
A16AX18 LUMASIRAN
Atc Name
a 16 ax 18
Aig Number
0163440001
Company Name
Alnylam Netherlands BV
Company Address
Antonio Vivaldistraat 150, Amsterdam, --, Netherlands, 1083 HP
Company Detail Path
/organization/alnylam-netherlands-bv
Company Information
Pharmaceutical Company Name
Alnylam Netherlands BV
Country Name
Netherlands
Website
http://www.alnylam.com/alnylam-netherlands
Active Ingredients
LUMASIRAN (LUMASIRAN SODIUM)
94.5 MG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4990579d003c7935
Type
Standard
Back to Health Canada Approvals